Laplaud DA, Casey R, Barbin L, et al. - In patients followed prospectively in the Observatoire Français de la Sclérose en Plaques, researchers assessed the efficacy of teriflunomide (TRF) vs dimethyl fumarate (DMF) regarding both clinical and MRI outcomes in multiple sclerosis. The study sample consisted of 1,770 patients with relapsing-remitting multiple sclerosis (RRMS) with an available baseline brain MRI in intention to treat. The authors discovered comparable efficacy of DMF and TRF in terms of clinical results after 2 years of treatment, but better MRI-based outcomes were seen in patients treated with DMF, resulting in a lower rate of discontinuation due to lack of efficacy. Lack of effectiveness was reported by 8.5% of DMF-treated patients vs 14.5% of TRF-treated patients when asked for reasons for treatment withdrawal; adverse events accounted for 16% of TRF-treated patients and 21% of DMF-treated patients after 2 years.